Sign in
Taking peopleNo phase

Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

Key facts

Who runs it
Jamil Cedeño Mora
Where
Spain12 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,200 people, planned
Started
1 Oct 2025
Expected to end
1 Jan 2028
Type of study
Observational
Treatments tested
  • Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.
Record updated
15 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Other criteria

  • Eligible patients for this study must comply with the following requirements
  • ICU admission with a septic shock diagnosis
  • Age 18 years or above at ICU admission
  • Use of vasopressin as an adjunct of norepinephrine; For the purposes of this study, septic shock is defined by full compliance with the following criteria
  • Sustained arterial hypotension or serum lactate above 2 mmol/L
  • Adequate but unsuccessful fluid resuscitation
  • Vasopressor usage to maintain a mean arterial pressure above 65 mmHg
  • Probable or proven infectious etiology; Patients with some of the following conditions will be automatically excluded
  • Pregnancy
  • Ischemic cardiogenic shock
  • Acute intestinal ischemia
  • Readmission to the Intensive Care Unit

This trial is currently available in Spain.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock.

Read full original descriptionShow less

The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin.

The main research questions are:

* Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients?

Participants will:

* Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.

Treatments tested

  • Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Use of Vasopressin in Septic Shock.
Record updated
15 December 2025